Universal amplifier system for high-fidelity multi-modal biosignal recordings

描述(申请人提供)：生物电信号的测量、监测和使用已经从测量心脏的电活动发展到涵盖从心脏、骨骼肌和平滑肌肉到脑和周围神经组织的各种组织。伴随着这一发展的是专门设备的发展，以捕获和解释这些微小的信号。然而，生物电信号测量的未来正朝着多个源、多个位置的测量和集成方向发展，这就带来了需要通过专门为特定信号设计的设备来集成信号和源的问题。为了解决这个问题，Refer2Input(R2i)及其印第安纳大学普渡大学(IUPUI)的研究伙伴在重新分析了测量和采集问题后，设计了新型的生物电压接器系统。由此产生的通用可逆放大器系统发挥了模拟和数字世界的优势，跨越了所有生物电信号的范围，并能够在不重新配置硬件的情况下重新聚焦到特定信号。在这次STTR中，R2i和它在IUPUI的研究伙伴将进一步开发这项技术，并证明其可行性。第一阶段的具体目标是：1)开发和实施硬件平台；2)开发和实施软件平台；3)完成硬件和软件系统的体内验证。经过验证和测试的UIA系统将形成基础仪器基础，在此基础上将在第二阶段开发多模式、多频率的应用程序。该系统利用了UIA系统的硬件通用性和实时重新聚焦能力，对此存在着相当大的商业市场。该系统将简化研究和临床实验室的仪器需求，通过汇聚到单一的通用记录平台来降低成本。

DESCRIPTION (provided by applicant): The measurement, monitoring and use of bioelectric signals has evolved from the measurement of the electrical activity of the heart to encompass tissues ranging from cardiac, skeletal and smooth muscles, to brain and peripheral nerve tissues. Together with this development has been the evolution of specialized equipment to capture and interpret these minute signals. However, the future of bioelectric signals measurement is moving towards the measurement and integration of multiple sources, and multiple locations, which leads to the problem of the need to integrate signals and sources through specialized equipment designed for specific signals. To overcome this problem, Refer2Input (R2i) and its research partners at Indiana University Purdue University (IUPUI) designed novel bioelectric compander system following a reanalysis of the measurement and acquisition problem. The resulting Universal Invertible Amplifier system plays to the strengths of the analog and digital world to span the range of all bioelectric signals coupled with the ability o refocus to specific signals without hardware reconfiguration. In this STTR, R2i and its research partner at IUPUI will further develop this technology and demonstrate feasibility. Phase I Specific Aims are: 1) Develop and implement the hardware platform 2) Develop and implement the software platform and, 3) Complete in- vivo validation of the hardware and software system. The validated and tested UIA system will form the foundational instrumentation basis upon which a multi-modal, multi-frequency applications will be developed in Phase II. This system takes advantage of the universality of the hardware and the real-time refocus abilities of the UIA system, for which a considerable commercial market exists. The system will simplify the instrumentation needs of research and clinical laboratories, reducing costs through convergence to a single common recording platform.